Treating residual insomnia in schizophrenia: Examining the options

Acta Psychiatrica Scandinavica

Volumn 127, Issue 1, 2013, Pages 11-

  Andrade, C ^a   Suresh Kumar, P N ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^b KMCT Medical College   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE; MELATONIN; ZOLPIDEM; ZOPICLONE;

BEHAVIOR THERAPY; DISINHIBITION SYNDROME; HUMAN; INSOMNIA; MENTAL PATIENT; NOTE; PRIORITY JOURNAL; PSYCHOPATHY; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA;

EID: 84871102131     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12019     Document Type: Note

References (5)

1. Baandrup L, Jennum P, Lublin H, Glenthoj B. Treatment options for residual insomnia in schizophrenia. Acta Psychiatr Scand 2013;127:81-82.
2. Kumar PNS, Andrade C, Bhakta SG, Singh NM. Melatonin in schizophrenic outpatients with insomnia: a double-blind, placebo-controlled study. J Clin Psychiatry 2007;68:237-241.
3. Sharma MP, Andrade C. Behavioral interventions for insomnia: theory and practice. Indian J Psychiatry 2012; (in press).
4. Stimmel GL. Benzodiazepines in schizophrenia. Pharmacotherapy 1996;2:148S-151S; discussion 166S-168S.
5. Stahl SM. Antipsychotic polypharmacy: never say never, but never say always. Acta Psychiatr Scand 2012;125:349-351.